|
|
Home
The Word Brain
|
My Amedeo
FAQ
Privacy
About
|
For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF |
| Bladder Cancer |
| Single Articles |
AMEDEO Bladder Cancer is free of charge.
An interpretable contrast-enhanced CT-based cross-attention transformer model for
predicting progression-free survival in muscle-invasive bladder cancer: a
multicenter study.
Abdom Radiol (NY). 2026 Oct 22. doi: 10.1007/s00261-026-05837.
PubMed
Abstract available
Age as a pre-operative predictor of uterine, bladder, and intestinal invasion in
cervical cancer.
Acta Radiol. 2026 Sep 16:2841851261486043. doi: 10.1177/02841851261486043.
PubMed
Abstract available
Multitask Deep Learning Model for Predicting Lymph Node Metastasis and
Disease-Free Survival From Cytology Images in Bladder Cancer: A Multicenter Study
With Pan-Cytology Validation.
Adv Sci (Weinh). 2026 Oct 21:e76577. doi: 10.1002/advs.76577.
PubMed
Abstract available
Perioperative pembrolizumab or placebo plus neoadjuvant cisplatin and gemcitabine
in participants with muscle-invasive bladder cancer who are eligible for
cisplatin: the double-blind, phase III KEYNOTE-866 study.
Ann Oncol. 2026 Oct 23:S0923-7534(26)06888-2. doi: 10.1016/j.annonc.2026.
PubMed
Abstract available
Neoadjuvant nivolumab plus gemcitabine-cisplatin followed by postsurgical
adjuvant nivolumab versus neoadjuvant gemcitabine-cisplatin in patients with
muscle-invasive bladder cancer: final results from the phase III CA017-078 trial.
Ann Oncol. 2026 Dec 31:S0923-7534(26)06877-8. doi: 10.1016/j.annonc.2026.
PubMed
Abstract available
Enfortumab vedotin plus pembrolizumab in cisplatin-eligible muscle-invasive
bladder cancer: efficacy proven, duration unclear.
BJU Int. 2026 Oct 21. doi: 10.1111/bju.70507.
PubMed
NEITHER study: NICE versus EAU inconsistent triage, expenses and reliability in
non-high-risk non-muscle invasive bladder cancer surveillance.
BJUI Compass. 2026;7:e70283.
PubMed
Abstract available
A prospective randomized controlled trial comparing subpectineal and interfascial
obturator nerve block techniques in preventing adductor muscle spasm during
transurethral resection of bladder tumors.
BMC Anesthesiol. 2026;26:622.
PubMed
Abstract available
Investigation of the significance and role of androgen receptor expression in
basal/squamous type urothelial carcinoma cell line J82 cells.
BMC Cancer. 2026;26:1283.
PubMed
Abstract available
Guidewire-assisted en bloc resection of periorifice non-muscle-invasive bladder
cancer: a retrospective case series.
BMC Urol. 2026;26:252.
PubMed
Abstract available
Predicting acute kidney injury after radical cystectomy for muscle-invasive
bladder cancer.
BMC Urol. 2026;26:253.
PubMed
Abstract available
Capsaicin enhances chemosensitivity and mitigates MMP11-driven aggressiveness in
human bladder cancer.
Cancer Cell Int. 2026;26:346.
PubMed
Abstract available
Metabolic Competition-Driven Antitumor Immunity of glpX-Deficient Engineered
Salmonella via Glucose Deprivation and STING Activation in Bladder Cancer.
Cancer Commun (Lond). 2026;46:0060.
PubMed
Abstract available
Before the seeds arrive: pre-metastatic niche orchestration in bladder cancer.
Cancer Metastasis Rev. 2026;45:79.
PubMed
Abstract available
The NEK8/ALYREF axis promotes cisplatin resistance in bladder cancer by
stabilizing CDK18 mRNA to facilitate DNA damage repair.
Cell Death Differ. 2026 Oct 19. doi: 10.1038/s41418-026-01883.
PubMed
Abstract available
NEK2-AURKA axis drives ubiquitin-dependent IFT88 degradation to suppress
ciliogenesis and promote basal-type bladder cancer.
Cell Death Dis. 2026;17:903.
PubMed
Abstract available
The novel biguanide derivative 4C synergizes with talazoparib by inducing
ferroptosis via the SREBP1/FASN/ SLC7A11/GPX4 axis in bladder cancer.
Cell Death Discov. 2026;12:423.
PubMed
Abstract available
FGFR3 mRNA expression in urothelial bladder cancer: Associations with tumor
phenotype without prognostic impact.
Cent European J Urol. 2026;79:295-302.
PubMed
Abstract available
Cytoreductive cystectomy combined with chemotherapy versus chemotherapy alone in
the treatment of metastatic bladder cancer: A retrospective comparative study.
Cent European J Urol. 2026;79:233-242.
PubMed
Abstract available
Intradiverticular Bladder Cancer Mimicking a Normal Urinary Bladder Diverticulum
on FDG PET/CT.
Clin Nucl Med. 2026 Oct 20. doi: 10.1097/RLU.0000000000006729.
PubMed
Abstract available
Clinical advances and practice updates in genitourinary cancers: a 2025 review
from the multidisciplinary Spanish 'Cambados annual meeting'.
Clin Transl Oncol. 2026;28:5031-5054.
PubMed
Abstract available
The Current Status and Evaluation of Artificial Intelligence in Bladder Cancer:
Clinical Applications and Research.
Comput Struct Biotechnol J. 2026;35:0197.
PubMed
Abstract available
Novel Imaging Techniques Prior to Surgical Management of Invasive Bladder Cancer:
A Systematic Review.
Curr Urol Rep. 2026;27:58.
PubMed
Abstract available
AFF3 regulates ferroptosis and malignant progression in bladder cancer cells via
the NRF2/GPX4 signaling axis.
Eur J Histochem. 2026;70.
PubMed
Abstract available
Validation of a Computational Histology Artificial Intelligence-based Biomarker
for BCG Treatment in Non-muscle-invasive Bladder Cancer in the ANZUP 1301
Randomized Phase 3 Trial.
Eur Urol. 2026 Oct 21:S0302-2838(26)02433-4. doi: 10.1016/j.eururo.2026.
PubMed
Clinical Outcomes of Bladder-sparing Management Versus Early Radical Cystectomy
in cT1 Micropapillary Bladder Cancer: A Systematic Review and Meta-analysis.
Eur Urol Oncol. 2026 Oct 20:S2588-9311(26)00275.
PubMed
Abstract available
Circulating Plasma and Urine Tumor DNA in Non-muscle-invasive Bladder Cancer: A
Promising Biomarker to Guide Therapeutic Intensification.
Eur Urol Open Sci. 2026;92:71-74.
PubMed
Abstract available
Bioengineering strategies to enhance BCG immunotherapy against bladder cancer.
Front Immunol. 2026;17:1888889.
PubMed
Abstract available
Reprogramming innate immune memory in bladder cancer: the proposed bone
marrow-bladder axis and next-generation BCG-based immunotherapies.
Front Immunol. 2026;17:1945559.
PubMed
Abstract available
Integrated analyses identify MAN1B1 as a candidate regulator of chemotherapeutic
tolerance and immunosuppression in bladder cancer.
Front Immunol. 2026;17:1958628.
PubMed
Abstract available
Risk factors for recurrence after initial transurethral resection of bladder
tumor in patients with non-muscle-invasive bladder cancer.
Front Oncol. 2026;16:1861461.
PubMed
Abstract available
Population-specific molecular features and clinical significance of urinary tumor
DNA mutations in Chinese patients with newly diagnosed non-muscle-invasive
bladder cancer.
Front Oncol. 2026;16:1914617.
PubMed
Abstract available
Echinocystic acid inhibits the growth of human bladder cancer cells by
suppressing AKT1/GSKbeta/beta-Catenin signaling and synergizes with gemcitabine.
Genes Dis. 2026;14:102148.
PubMed
Abstract available
Microbiome-urothelium crosstalk in bladder cancer: From dysbiosis to clinical
translation.
IMetaOmics. 2026;3:e70081.
PubMed
Abstract available
Integrin alpha5beta1-mediated multicellular crosstalk in the tumor microenvironment
drives bladder cancer progression and reveals targetable vulnerabilities.
IMetaOmics. 2026;3:e70102.
PubMed
Abstract available
Circulating and tumor microenvironment immunomarkers associate with immunotherapy
efficacy in advanced bladder urothelial carcinoma: an exploratory multicenter
study integrating genomic and immunophenotypic profiling.
Immunotherapy. 2026;18:1111-1125.
PubMed
Abstract available
Bladder cancer in Africa, 2010-2023: burden, geographic heterogeneity,
demographic drivers, pandemic-era temporal changes, and projections to 2030.
Infect Agent Cancer. 2026;21:69.
PubMed
Abstract available
Exon-6 truncated p53 Suppresses Innate Immune Responses to Facilitate Immune
Evasion in Bladder Cancer.
Int J Biol Sci. 2026;22:8251-8270.
PubMed
Abstract available
Patient-reported outcome sub-analysis of a phase 2 trial of bladder preservation
therapy with atezolizumab and radiation therapy (BPT-ART) for invasive bladder
cancer.
Int J Clin Oncol. 2026 Oct 22. doi: 10.1007/s10147-026-03226.
PubMed
Abstract available
Changes in Treatment Patterns and Survival Outcomes Across Therapeutic Eras in
Metastatic Urothelial Carcinoma: A Multicenter Real-World Study.
Int J Urol. 2026;33:e70679.
PubMed
Abstract available
Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle-Invasive
Urothelial Carcinoma.
Int J Urol. 2026;33:e70664.
PubMed
Abstract available
Two-step enucleation combined with needle electrode: a modified TURBT technique
to enhance detrusor muscle detection.
Int Urol Nephrol. 2026;58:4739-4750.
PubMed
Abstract available
Federated Learning-Based Multi-Task Framework for Privacy-Preserving Diagnosis of
Muscle Invasion in Bladder Cancer.
J Imaging Inform Med. 2026 Oct 22. doi: 10.1007/s10278-026-02429.
PubMed
Abstract available
Preclinical Evaluation of 89Zr-Labeled Anti-Nectin-4 Antibody for Enhanced PET
Imaging in Bladder Urothelial Carcinoma.
J Med Chem. 2026;69:24388-24399.
PubMed
Abstract available
Cost-Effectiveness of Perioperative Enfortumab Vedotin and Pembrolizumab for
Bladder Cancer.
JAMA Netw Open. 2026;9:e2640370.
PubMed
Abstract available
Spatial Transcriptomics of Micropapillary, Plasmacytoid, and Sarcomatoid
Urothelial Carcinoma Reveals Distinct Molecular Landscapes.
Lab Invest. 2026;106:106160.
PubMed
Abstract available
Single, early intravesical instillation of pirarubicin in the prevention of
bladder recurrence after radical nephroureterectomy for upper tract urothelial
carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 2026;27:973-982.
PubMed
Abstract available
Bladder preservation is still feasible in the rare aggressive small cell
carcinoma subtype.
Med Oncol. 2026;43:339.
PubMed
Abstract available
MG53 suppresses the progression of bladder cancer through E3 ubiquitin
ligase-mediated degradation of AMPKalpha.
Med Oncol. 2026;43:337.
PubMed
Abstract available
Development and validation of a ferroptosis and metabolic reprogramming gene
signature for risk stratification in bladder urothelial carcinoma: A
retrospective multicohort study.
Medicine (Baltimore). 2026;105:e51078.
PubMed
Abstract available
Mutational Signatures and Hypermutation Phenotypes Define Bladder Cancers Arising
in Waterpipe and Cigarette Smokers.
Mol Cancer Res. 2026 Oct 20. doi: 10.1158/1541-7786.MCR-26-0157.
PubMed
Abstract available
Single?cell multi?omics analysis reveals TGF-beta1-RUNX2-mediated matCAF
differentiation and its role in remodeling the lymph node metastatic
microenvironment in bladder cancer.
Oncogene. 2026 Oct 23. doi: 10.1038/s41388-026-04022.
PubMed
Abstract available
Prognosis and tumor grading in bladder urothelial carcinomas with intratumoral
grade heterogeneity.
Pathol Oncol Res. 2026;32:1612553.
PubMed
Abstract available
Comparison of oral 5-aminolevulinic acid-induced hypotension between general and
spinal anesthesia during photodynamic diagnosis-assisted transurethral resection
of bladder tumor for non-muscle invasive bladder cancer.
Photodiagnosis Photodyn Ther. 2026 Oct 22:105685.
PubMed
Abstract available
DAG-informed analysis of muscle characteristics and overall survival in patients
receiving radical treatment for bladder cancer.
Radiother Oncol. 2026 Oct 21:111831. doi: 10.1016/j.radonc.2026.111831.
PubMed
Abstract available
METASTATIC UROTHELIAL CARCINOMA OF THE BLADDER TO THE RETINA: A CLINICOPATHOLOGIC
CORRELATION AND REVIEW OF THE LITERATURE.
Retina. 2026;46:2076-2080.
PubMed
Abstract available
NU-1025 modulates immunogenic cell death in bladder cancer: A multi-omics
insight.
SLAS Technol. 2026;43:100476.
PubMed
Abstract available
Recovery after cystectomy and urinary diversion: patient experiences and
challenges.
Support Care Cancer. 2026;34:1113.
PubMed
Abstract available
Integrative single-cell and computational pathology analyses reveal a
C11orf24-associated stem-like epithelial population linked to tumor
microenvironment remodeling and immune evasion in bladder cancer.
Transl Oncol. 2026;74:103082.
PubMed
Abstract available
Patient-reported outcome-informed individualized dose and schedule modification
of enfortumab vedotin plus pembrolizumab in a nonagenarian patient with
metastatic bladder cancer: a case report.
Urol Int. 2026 Oct 21:1. doi: 10.1159.
PubMed
Abstract available
Metachronous Contralateral Recurrence in Upper Tract Urothelial Carcinoma: A
Multi-Institutional Competing-Risks Analysis From the ROBUUST 3.0 Registry.
Urol Pract. 2026;13:623-632.
PubMed
Abstract available
Timing of FDA-Defined Adequate BCG Therapy and Oncologic Outcomes in High-Risk
Non-Muscle-Invasive Bladder Cancer.
Urol Pract. 2026 Oct 23:101097UPJ0000000000001109.
PubMed
Abstract available
A prospective cohort study to assess the diagnostic accuracy of VI-RADS score in
a tertiary center in central India.
Urologia. 2026;93:682-687.
PubMed
Abstract available
Comparison of complications in our extraperitoneal radical cystoprostatectomy
with orthotopic urinary diversion cases and the intraperitoneal approach reported
in the literature.
Urologia. 2026;93:674-681.
PubMed
Abstract available
Clinical response outweighs baseline nodal stage in treatment selection and
survival of clinically node-positive bladder cancer.
World J Urol. 2026;44:759.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
